Join Growin Stock Community!

Vanda pharmaceuticals inc.VNDA.US Overview

US StockHealthcare
(No presentation for VNDA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VNDA AI Insights

VNDA Overall Performance

VNDA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VNDA Recent Performance

-5.02%

Vanda pharmaceuticals inc.

0.05%

Avg of Sector

-0.31%

S&P500

VNDA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VNDA Key Information

VNDA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VNDA Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Price of VNDA

VNDA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VNDA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.73
PE Ratio (TTM)
-
Forward PE
19.93
PS Ratio (TTM)
2.44
PB Ratio
1.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
93.96%
Net Margin
-102.02%
Revenue Growth (YoY)
8.72%
Profit Growth (YoY)
8.32%
3-Year Revenue Growth
-3.91%
3-Year Profit Growth
-2.86%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.73
PE Ratio (TTM)
-
Forward PE
19.93
PS Ratio (TTM)
2.44
PB Ratio
1.55
Price-to-FCF
-
Gross Margin
93.96%
Net Margin
-102.02%
Revenue Growth (YoY)
8.72%
Profit Growth (YoY)
8.32%
3-Year Revenue Growth
-3.91%
3-Year Profit Growth
-2.86%

  • When is VNDA's latest earnings report released?

    The most recent financial report for Vanda pharmaceuticals inc. (VNDA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VNDA's short-term business performance and financial health. For the latest updates on VNDA's earnings releases, visit this page regularly.

  • What is the operating profit of VNDA?

    According to the latest financial report, Vanda pharmaceuticals inc. (VNDA) reported an Operating Profit of -40.35M with an Operating Margin of -70.53% this period, representing a decline of 292.58% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is VNDA's revenue growth?

    In the latest financial report, Vanda pharmaceuticals inc. (VNDA) announced revenue of 57.22M, with a Year-Over-Year growth rate of 7.58%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does VNDA have?

    At the end of the period, Vanda pharmaceuticals inc. (VNDA) held Total Cash and Cash Equivalents of 84.85M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does VNDA go with three margins increasing?

    In the latest report, Vanda pharmaceuticals inc. (VNDA) did not achieve the “three margins increasing” benchmark, with a gross margin of 93.3%%, operating margin of -70.53%%, and net margin of -246.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VNDA's profit trajectory and future growth potential.

  • Is VNDA's EPS continuing to grow?

    According to the past four quarterly reports, Vanda pharmaceuticals inc. (VNDA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VNDA?

    Vanda pharmaceuticals inc. (VNDA)'s Free Cash Flow (FCF) for the period is -29.52M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 1,353.42% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of VNDA?

    The latest valuation data shows Vanda pharmaceuticals inc. (VNDA) has a Price-To-Earnings (PE) ratio of -1.64 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.